PubMed Health⌕ Search

Biomedical subjects

R G Carbonell

Publications and source records attributed to R G Carbonell.

20 records · Page 2Linked to original sources

Competitive immunosorbent assays using ligand-enzyme conjugates bifunctional liposomes: theory and experiment.

Two models of immunoadsorbent assays are developed that describe the competitive adsorption of labeled antigen and unlabeled analyte to antibody binding sites immobilized on a solid surface. In the first model, a small labeled antigen and a small unlabeled analyte compete with only binding site limitations and no steric limitations. A multicomponent langmuir isotherm results that is sufficient to quantify competitive adsorption. This model can describe, with no adjustable parameters, the data of competitive assays for biotin using biotinylated horseradish peroxidase (B-HRP) over a wide range of anti-biotin antibody (ABA) surface densities. In the second model, the small unlabeled analyte competes with a large colloidal particle containing many antigens and enzyme labels attached to its surface. This model quantifies the steric interference that large particles can experience upon binding (large ligand effect) due to the lower probability of finding an available area of the right size to accommodate the larger adsorbent. This large ligand model also takes into account the increased probability of binding a large particle due to the larger number of antibody binding sites covered per collision. The resulting model is used to analyze the competitive assay data of biotin competing with liposomes to which many biotin and HRP molecules have been conjugated. This analysis is of interest because previous work has shown that these bifunctional liposomes can reduce the detection limit for antigens in bulk solution relative to assays performed with conventional small labeled antigens.

Binding, Competitive↗

Preparation and characterization of liposomal systems entrapping the boronated compound o-carboranylpropylamine.

Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when the stable isotope, Boron-10, is irradiated with low-energy thermal neutrons to yield ionizing Helium and Lithium ions that are highly damaging and usually lethal to cells. The successful treatment of cancer by BNCT requires the selective concentration of Boron-10 within malignant tumours. Liposomes have been used as therapeutic compound delivery vehicles for in vivo application, including several anticancer agents. The ability of the boron-containing compound, o-carboranylpropylamine chloride, to accumulate within unilamellar liposomes in response to a transmembrane pH gradient is evaluated. Characterization of the systems obtained is performed for conventional and polyethylene glycol (PEG)-modified (stealth) liposomes, in terms of lipid and CPA contents, vesicle size and stability in detergent solutions. Results demonstrate that CPA loading and vesicle stability can be controlled by the experimental procedure. The loading of CPA into liposomes with average diameters of 100 nm is estimated at 13000 molecules per vesicle for the most stable systems. CPA toxicity to normal human peripheral blood lymphocytes and to adherent glioblastoma multiforme SK-MG-1 cells in vitro is observed to decrease as a result of the entrapment of CPA in liposomes.

Boron Compounds↗